Original Source(s)
Related Content
FDA Approves First Oral PCSK9 Inhibitor
Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.
July 16, 2026
-
2 min
ASE Plenary: Progress, Priorities, and What’s Next
Efforts to align, sustain, and engage drove a year of growth for ASE.
June 26, 2026
-
4 min